Individualized Functional Connectivity Targeting in aiTBS for Depression
| Condition | Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder |
|---|---|
| Phase | Phase 2 |
| Sponsor | Brigham and Women's Hospital |
| Status | Completed |
| Enrollment | 40 participants |
| Interventions | transcranial magnetic stimulation |
| Start date | Jul 15, 2023 |
| Completion date | Mar 17, 2025 |
| Results posted | Jul 7, 2026 |
Summary
The goal of this clinical trial is to estimate the importance of neuroimaging in accelerated intermittent theta burst stimulation (aiTBS) for depression. Participants will receive aiTBS treatment, but they will not know if their treatment spot was found with neuroimaging or head measurements.
Montgomery-Åsberg Depression Rating Scale (MADRS)
| Connectivity-based Targeting | 35 Scores on scale |
|---|---|
| Scalp-based Targeting | 31 Scores on scale |
| Connectivity-based Targeting | 6 Scores on scale |
| Scalp-based Targeting | 11 Scores on scale |
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- CBT+ for Depression — University of Wisconsin, Madison
- Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
- Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
- Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
- A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
- Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders — Massachusetts General Hospital